期刊
JOURNAL OF THE NEUROLOGICAL SCIENCES
卷 278, 期 1-2, 页码 64-65出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jns.2008.11.014
关键词
Migraine; Topiramate; Weight loss; Body mass index (BMI)
Topiramate (TPM) is generally recognized efficacious and safe in migraine prevention. A significant proportion of patients undergoing TPM administration may show weight loss. In epileptic subjects, high body mass index (BMI) was found to be predictive of weight loss under TPM therapy. We therefore aimed to study whether common clinical determinants may be associated to TPM weigh loss in migraine patients. In our clinical series, high BMI was not found a predictor of weight loss under TPM treatment. Unknown genetic and environmental factors that may determine the courses of weight loss under TPM therapy are still do be identified. (c) 2008 Elsevier B.V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据